Human Mesenchymal Stem Cells Improve Myocardial Performance in a Splenectomized Rat Model of Chronic Myocardial Infarction  by Liu, Jen-Fu et al.
J Formos Med Assoc | 2008 • Vol 107 • No 2 165
Stem cell therapies hold promise for the treatment
of ischemic cardiovascular disease.1–4 Stem cells are
pluripotent and have the property of self-renewal
as well as multilineage differentiation.5 Therefore,
stem cells make it possible to regenerate damaged
cells.6 The bone marrow is home to mesenchymal
stem cells (MSCs) that are able to differentiate into
many different cell types.7 Bone marrow-derived
cells are autologous, abundant, and relatively
easy to harvest; they do not require immune sup-
pression, and they are associated with less ethical
concern than fetal or neonatal heart cells. These
Human Mesenchymal Stem Cells Improve
Myocardial Performance in a Splenectomized
Rat Model of Chronic Myocardial Infarction
Jen-Fu Liu,1 Bao-Wei Wang,1 Huei-Fong Hung,1 Hang Chang,2 Kou-Gi Shyu1,3*
Background/Purpose: Cellular therapy has been applied to animal studies and clinical trials for acute or
subacute myocardial infarction. Little is known about the effect of cell therapy on chronic myocardial in-
farction. The goal of this study was to investigate myocardial performance after human bone marrow-derived
mesenchymal stem cell (hMSCs) transplantation in rats with chronic myocardial infarction.
Methods: The hMSCs were obtained from adult human bone marrow and expanded in vitro. The purity
and characteristics of hMSCs were identified by flow cytometry and immunophenotyping. Splenectomy
in male rats was performed to prevent immune reaction. One week after splenectomy, ligation of the left
anterior descending coronary artery was performed to induce myocardial infarction. Four weeks after ligation
of the coronary artery, culture-expanded hMSCs were injected intramyocardially at the left anterior free
wall. Left ventricular function measured by echocardiography, infarct size and immunohistochemical
stain were performed to evaluate the effect of the therapy.
Results: The engrafted hMSCs were positive for the cardiac marker troponin T. Infarct size (35.4 ± 3.4% vs.
53.3 ± 3.0%, p < 0.001) and fibrotic area (2.6 ± 0.1% vs. 5.9 ± 0.2%, p < 0.001) were significantly smaller in
the hMSC-treated group than in the control group at 28 days after therapy. hMSC transplantation resulted
in smaller left ventricular end-diastolic dimension (6.5 ± 0.1 mm vs. 7.9 ± 0.7 mm, p < 0.001) and better
left ventricular ejection fraction (88.7 ± 1.2% vs. 65.8 ± 2.5%, p < 0.001) than in the control group.
Capillary density was markedly increased after hMSC transplantation compared with the control group.
Conclusion: This study demonstrates that intramyocardial transplantation of hMSCs improves cardiac
function after chronic myocardial infarction through enhancement of angiogenesis and myogenesis in the
ischemic myocardium. Transplantation of hMSCs for myocardial regeneration may become the future
therapy for chronic myocardial infarction. [J Formos Med Assoc 2008;107(2):165–174]
Key Words: cellular therapy, mesenchymal stem cells, myocardial infarction, myocardial regeneration
©2008 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1Division of Cardiology and 2Department of Emergency Medicine, Shin Kong Wu Ho-Su Memorial Hospital, and
3Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Received: April 3, 2007
Revised: June 15, 2007
Accepted: October 2, 2007
*Correspondence to: Dr Kou-Gi Shyu, Division of Cardiology, Shin Kong Wu Ho-Su
Memorial Hospital, 95 Wen-Chang Road, Taipei 111, Taiwan.
E-mail: shyukg@ms12.hinet.net
ORIGINAL ARTICLE
characteristics make bone marrow-derived cells
uniquely suited to the task of restoring structure
and function in the wake of a myocardial infarc-
tion.8 As damaged tissue may lose anatomic cues
for functioning organ neovascularization, in vitro
manipulation of stem cells may be essential to 
facilitate in vivo incorporation.
MSCs have been shown to improve heart
function in acute myocardial infarction9–11 and
chronic myocardial ischemia.12 However, little is
known about the effect of MSCs on heart func-
tion in chronic myocardial infarction.13 Therefore,
the aim of the present study was to investigate
whether MSC therapy can improve cardiac per-
formance after chronic myocardial infarction. 
To investigate the potential therapeutic utility 
for clinical application, we used human MSCs
(hMSCs) in the present study.
Methods
Isolation and culture of human bone
marrow-derived MSCs
Bone marrow derived hMSCs were isolated and
cultured according to a previously reported
method by Pittenger et al.14 Briefly, after informed
consent, the donor marrows obtained from
healthy volunteers were suspended with buffered
PBS supplemented with 12.5 U/mL heparin,
50 U/mL penicillin, and 50 mg/mL streptomycin.
Bone marrow was obtained from healthy donors
because of ethical problem and risk factor for
coronary artery disease reducing capacity of pro-
genitor cells.15 Subjects were informed that their
genetic material would be transferred to animals.
Mononucleated cells were isolated by ficol density
gradient, washed and resuspended in Dulbecco’s
modified Eagle’s medium-low glucose supple-
mented with 10% fetal bovine serum (Hyclone),
and cultured at 37°C and 5% CO2. Seven days
later, individual colonies were collected, iso-
lated, cultured and expanded. When the cultures
reached 80% confluence, the cells were recovered
by 0.25% trypsin-1 mM EDTA and followed by
passages.
Immunophenotyping of cultured MSCs
Analysis of cell surface molecules was made on
hMSCs using flow cytometry (Becton Dickinson,
Franklin Lakes, NJ, USA) by following the manu-
facturer’s instructions. hMSCs were analyzed by
direct or indirect immunofluorescence. To detect
surface antigens, cells were detached with 0.25%
trypsin-1 mM EDTA in PBS, washed with PBS
containing 2% bovine serum albumin and 0.1%
sodium azide (Sigma, St Louis, MO, USA), and
incubated with the respective antibody at a con-
centration previously established by titration. For
indirect immunofluorescence assays, cells were
washed and incubated with secondary antibody
(FITC conjugated goat anti-mouse second anti-
body). In each case, 1 × 104 cells were acquired
and analyzed by using the CellQuest software
(Becton Dickinson).
Rat model of chronic myocardial infarction
To prevent immune reaction to the transplanted
hMSCs, splenectomy was performed in adult
male Sprague-Dawley rats. A week after splenec-
tomy, permanent occlusion of the left anterior
descending coronary artery (LAD) was performed
to induce myocardial infarction. After induction
of anesthesia with isoflurane (3%), tracheotomy
was performed and the animal was ventilated on
a Harvard Rodent Respirator. An anterior thora-
cotomy was performed to open the pericardium.
The heart was then rapidly exteriorized, and an
8-0 silk suture was tightened around the proximal
LAD (before the first branch of diagonal artery).
Sham-operated control animals were prepared 
in a similar manner, except that the LAD was not
occluded. Splenectomy was also performed in
the sham-operation control group. Four weeks
after induction of myocardial infarction, the
pericardium was opened again using the proce-
dure described above. Animals were randomized
to either direct injection of hMSCs or normal
saline to the left ventricular free wall. After the
procedure, the chest wound was sutured and the
rats were allowed to recover. The study conformed
to the guidelines issued in the Guide for the Care
and Use of Laboratory Animals published by the
J.F. Liu, et al
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US National Institutes of Health (NIH Publication
No. 85-23, revised 1996).
Intramyocardial injection of stem cells
The rats after chronic myocardial infarction were
randomly chosen to receive hMSCs or saline
therapy. Four weeks after ligation of the LAD,
1 × 106 culture-expanded hMSCs resuspended in
50 µL of normal saline were injected intramy-
ocardially at the left anterior free wall by using
an insulin syringe with a 30-gauge needle. After
the left ventricle was accessed, the needle was ad-
vanced along the left ventricular free wall and
hMSCs or normal saline were injected over a pe-
riod of 5–10 seconds at three separate sites. The
injected sites were chosen to be at least 5 mm
away from the left ventricular apex. Aspiration
was done to confirm that the injection had been
into the left ventricular wall and not into the left
ventricular cavity.
Physiologic assessment of left ventricular
function
Transthoracic echocardiography (Acuson Sequoia
512 machine using a 15-MHz probe; Siemens
Medical Solutions USA Inc., Malvern, PA, USA)
was performed just before (baseline) and 28 days
after saline injection or hMSC transplantation.
Left ventricular diastolic and systolic dimensions
and fractional shortening were measured at the
midpapillary muscle level. The echocardiographic
examination was performed by a blinded observer.
Infarct size determination
Four weeks after intramyocardial transplantation,
mice were deeply anesthetized with isoflurane
(3%) and killed by rapid excision of the heart.
The excised hearts were immediately soaked in
cold saline for 10 seconds to remove excess blood
from the ventricle and fixed in neutral-buffered
4% formalin for 48 hours. Paraffin-embedded
samples were sectioned at 10 µm, and Masson’s
trichrome staining was performed to delineate
scar tissue from viable myocardium. Masson’s
trichrome-stained sections were captured as digital
images and analyzed by NIH Image software.
The infarct size was determined by triphenylte-
trazolium chloride method as previously de-
scribed.9 Each heart was cut in cross-section at
four levels from apex to base and prepared for
routine histology. The examiner of the tissue sec-
tions was blinded to the treatments. Infarct size
was determined as described previously.9
Immunohistochemical assessment of
transplanted myocardium
On the day of sacrifice (28 days after intramy-
ocardial transplantation), the left ventricle was
harvested and fixed in methanol and sliced into
5 µm paraffin sections. To block endogenous 
peroxide activity and nonspecific binding, sections
were incubated with 3% hydrogen peroxide fol-
lowed by 10% normal horse serum. Specimens
were incubated with a monoclonal anti-mouse
CD31 antibody or anti-troponin T antibody at
4°C overnight. Bound primary antibody was de-
tected with the avidin-biotin-immunoperoxidase
method (Signet Laboratories, Dedham, MA, USA).
Nonimmune normal rabbit IgG was used to con-
firm specificity. The number of capillaries was
counted in regions with transversely sectioned
myocytes in the border zone and in the area of
infarction. Capillary density was counted as de-
scribed previously.16 Incorporation of injected
hMSCs was verified by staining for HLA class 
I-APC (BD Pharmingen).
Specimens were also stained with troponin-T,
Tie-2, and PCNA monoclonal antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) to
confirm that transplantation of MSCs differentiate
to cardiomyocytes. The anti-Tie-2 and anti-PCNA
antibodies do not cross-react with human and
rat myocardium.
Statistical analysis
All results were expressed as mean ± standard de-
viation. Statistical significance was evaluated
using analysis of variance followed by Tukey-
Kramer multiple comparisons test (GraphPad
Software Inc., San Diego, CA, USA). A p value of
less than 0.05 was considered to denote statistical
significance.
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Results
Immunophenotypic characterization of
hMSCs
We used flow cytometric analysis and immuno-
phenotyping to confirm that the majority of 
adherent cells used in this study were MSCs. 
The bone marrow-derived MSCs were positive
for CD29, CD44, CD49, CD90, CD105, CD106,
CD166 and SH, but were negative for CD31,
CD45, KDR, Flt1 and Flt3. These data were con-
sistent with the properties of documented bone
marrow-derived MSCs. These results have been
shown in our previous study.9
Evidence of incorporation of hMSCs into
ischemic myocardium
A total of 79 rats received splenectomy and 75
survived the procedure (5% mortality rate). Seven
splenectomized rats in each group were used to
investigate the incorporation of hMSCs into heart
tissue. hMSCs were incorporated into the heart
by 14 days after transplantation, as evidenced by
the presence of HLA-positive myocytes within the
rat myocardium. The cells positive for HLA were
also positive for troponin-T, a cardiac myocyte
marker (Figure 1). There were 27 ± 4% of HLA-
positive myocytes in the left ventricle under high
power field microscope examination as calculated
by area.
hMSCs reduced infarct size
The infarct size was similar in each group at 
4 weeks after LAD ligation and before random-
ization for therapy (41 ± 5% for saline group and
42 ± 4% for MSC group). A total of 26 rats received
saline injection and 20 rats received hMSC injec-
tion. The survival rate after chronic infarction
and intramyocardial injection was 46% for the
control group and 55% for the hMSC group.
Although there was a trend toward better survival
for the hMSC group compared to the control
group, the difference did not reach statistical sig-
nificance. Infarct size (infarct area/total left ven-
tricular area) was significantly smaller in the
hMSC-treated animals (35.4 ± 3.4%) compared
to the control animals (53.3 ± 3.0%) or animals
injected with saline (54.9 ± 3.3%) (Figure 2).
Infarct size in splenectomized rats treated with
hMSCs was reduced by 34% compared to control
rats without treatment. Infarct size was similar
between the control group without treatment
and the saline-treated group. As shown in Fig-
ure 2, the fibrotic area as determined by Masson’s
trichrome stain decreased significantly from 5.9 ±
0.2% in the saline-treated group to 2.6 ± 0.1%
J.F. Liu, et al
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Figure 1. Representative photographs of immunohistochemical analysis using HLA-APC and troponin T antibodies. Positive
staining for HLA was shown in mesenchymal stem cell (MSC)-treated myocardium, but not in saline-treated myocardium.
Both groups stained positive for troponin T. Similar results were observed in another six independent experiments. The
left panel is hematoxylin and eosin (H&E) stained myocardium.
in the hMSC-treated group (p < 0.001). The 
fibrotic area was similar between the control
group without treatment and the saline-treated
group.
hMSCs improved cardiac function
The left ventricular ejection fraction (LVEF) was
similar in each group at 4 weeks after LAD liga-
tion and before randomization for therapy
(68 ± 3% for saline group and 67 ± 4% for MSC
group). The cardiac functional parameters evalu-
ated by echocardiography, 4 weeks after therapy,
are shown in the Table. In the control group,
markedly decreased fractional shortening and LVEF
with dilated left ventricular cavity (Figure 3) were
clearly seen. In the group that underwent hMSC
transplantation, significantly higher fractional
shortening and LVEF and smaller left ventricular
cavity were observed compared with the control
group without treatment and the saline-treated
group. The LVEF of hMSC-treated rats increased
by 35% compared to control rats without treat-
ment and increased by 37% compared to rats
treated with saline.
hMSCs increased capillary density
At 28 days after therapy, capillary density of the
ischemic myocardium in the hMSC-treated
Mesenchymal stem cells in chronic MI
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Figure 2. Mesenchymal stem cells (MSCs) reduced infarct size and fibrosis area. (A) Representative Masson’s trichrome
stain for cross sections of myocardium. AMI = chronic myocardial infarction without any treatment; Saline = treatment
with normal saline; MSC = treatment with human MSCs. (B) Quantitative analysis of fibrosis area. (C) Quantitative analysis
of infarct ratio. The infarct ratio represents infarction area divided by total left ventricular area. N = 10–12. *p < 0.001 vs.
MSC group.
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Table. Evaluation of cardiac function by echocardiography 4 weeks after cell therapy*
LVEDd (mm) LVEDs (mm) FS (%) LVEF (%)
Sham (n = 7) 6.8 ± 0.5 3.2 ± 0.1 52.3 ± 3.6 87.6 ± 2.8
Control (n = 10) 7.9 ± 0.7†‡ 5.3 ± 0.5†‡ 32.0 ± 1.8†‡ 65.8 ± 2.5†‡
Saline (n = 12) 7.8 ± 0.2†‡ 5.4 ± 0.6†‡ 31.5 ± 6.5†‡ 64.7 ± 9.4†‡
MSC (n = 11) 6.5 ± 0.1 3.0 ± 0.1 53.5 ± 1.7 88.7 ± 1.2
*Data are presented as mean ± standard deviation; †p < 0.001 vs. sham group; ‡p < 0.001 vs. MSC group. LVEDd = left ventricular end-
diastolic diameter; LVEDs = left ventricular end-systolic diameter; FS = fractional shortening; LVEF = left ventricular ejection fraction.
J.F. Liu, et al
170 J Formos Med Assoc | 2008 • Vol 107 • No 2
Figure 3. Representative echocardiographic
images at 4 weeks after intramyocardial
therapy. Smaller left ventricular end-
diastolic dimension and better contractility
were observed in the mesenchymal stem
cell (MSC)-treated group. AMI = chronic
myocardial infarction without any treatment;
Saline = treatment with normal saline.
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Figure 4. Mesenchymal stem cells (MSCs) increased capillary density.
(A) Photomicrographs show representative immunohistochemical
CD31 and hematoxylin and eosin (H&E) staining of ischemic 
myocardium from the border zone. The red dots indicate capillaries.
(B) Quantitative analysis of capillary density. N = 10–12. *p<0.001 vs.
MSC group.
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group (1110 ± 61/mm2) was significantly higher
than that in the control group without treatment
(396 ± 40/mm2) and the saline-treated group
(476±61/mm2) (Figure 4). Capillary density in the
border zone was 1300 ± 70/mm2 for the hMSC-
treated group, 940 ± 50/mm2 for the control group
without treatment, and 930 ± 46/mm2 for the
saline-treated group. Capillary density in the infarct
zone was 938 ± 42/mm2 for the hMSC-treated
group, 140 ± 12/mm2 for the control group with-
out treatment, and 144 ± 16/mm2 for the saline-
treated group. Capillary density in the border and
infarct zones was significantly higher in the MSC-
treated group than the control and saline-treated
groups.
hMSCs induced myogenesis
Seven heart tissues from splenectomized rats in
each group were used for immunohistochemical
study at 28 days after therapy. As shown in Figure 5,
immunohistochemical analysis showed that
stem cell markers, including Tie-2 and PCNA,
were all positive in the ischemic myocardium
treated with hMSCs. The myocytes that stained
positive for Tie-2 and PCNA also stained positive
for HLA. There were 55 ± 3% and 53 ± 3% of
HLA-positive MSCs in the myocardium that were
also Tie-2 and PCNA positive, respectively. These
marker-positive cells were cardiomyocytes. This
result indicates that the transdifferentiation per-
centage of MSCs is around 50%. Since bone mar-
row-derived stem cells express Tie-2, these data
suggest that hMSCs are capable of differentiating
into cardiomyocytes. Stem cell markers were not
stained in the ischemic myocardium treated with
saline. Some of the positive HLA-stained cells
were also positive for CD31 (Figure 5B), indicating
that some engrafting MSCs incorporate into 
vasculature to participate in vasculogenesis in
addition to enhancing angiogenesis. Since capil-
lary density was significantly higher in the 
MSC-treated group, our results indicate that the
origin of the capillaries is mostly from local 
endothelial cells and only a few are from HLA-
positive MSCs.
Discussion
The present study demonstrates that transplanta-
tion of adult hMSCs induces myocardial myogen-
esis and angiogenesis in a rat model of chronic
myocardial infarction. This model of therapy re-
duced infarction size and fibrosis area, improved
left ventricular function, and increased capillary
density. We have shown that highly purified
CD29+CD90+CD166+CD45–MSCs can be isolated
and expanded from human adult bone marrow
by immunoselection.9 Some of the engrafted
hMSCs stained by cardiac proteins such as tro-
ponin T also stained positive for Tie-2 and PCNA.
These results suggest that hMSCs differentiate into
cardiomyocytes. Our study also demonstrated that
some of the engrafted hMSCs stained by cardiac
proteins such as troponin T also stained positive
for CD31. This finding indicates that engrafting
MSCs incorporate into vasculature to participate
in both vasculogenesis and angiogenesis. When
demonstrating two phenotypes in the same cells,
it is better to use a confocal microscope for im-
munostaining. In the present study, without a high-
power laser-scanning confocal microscope, it was
very difficult to determine if these double-stained
cells were newly differentiated endogenous cells or
the product of cell fusion or transdifferentiation.
Myocardial dysfunction resulting from myo-
cardial infarction is a widespread and important
cause of morbidity and mortality in adults. Clinical
manifestations are enormous and heterogeneous
because of scar- and ischemia-related postinfarc-
tion events. Bone marrow-derived cells have been
used to regenerate damaged myocardium in pa-
tients with myocardial infarction. However, clin-
ical bone marrow-derived cell therapy resulted in
mixed results from mixed cells.17 Bone marrow-
derived cells have been shown to improve left
ventricular function and metabolism after chronic
infarction in a small clinical study.18 The effect 
of hMSCs in chronic myocardial infarction is
poorly understood. MSCs have the capacity to
engraft and survive long-term in distinctive target
tissue and can be isolated from several human
J.F. Liu, et al
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Figure 5. Representative microscope photographs for immunohistochemical staining. (A) The cells that stained positive
for Tie-2 and PCNA also stained positive for HLA. Similar results were observed in another six independent experiments.
(B) Some of the HLA-positive cells were also positive for CD31. Positive stain for HLA was shown in mesenchymal stem
cell (MSC)-treated myocardium but not in sham or saline-treated myocardium. Similar results were observed in another
six independent experiments.
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sources.19 MSCs exhibit a high ex vivo expansion
capacity. These characteristics make MSCs a good
choice of cell for cell therapy in dysfunctional
myocardium.
MSCs have been injected directly into the infarct
site, or they have been administered intravenously
and observed to home in to the site of injury.20,21
Most of the cell therapies for myocardial infarction
use MSCs of isogenic or allogeneic origins.10,22
Rarely have studies used hMSCs to treat myocardial
infarction in a rat model. Although Makkar et al
reported that allogeneic bone-marrow-derived
MSCs preserved cardiac function without im-
munosuppression,13 Grinnemo et al demonstrated
that transplant rejection of hMSCs can occur in 
a xenogenic model.23 Therefore, in this study, we
used splenectomized rats to prevent immune re-
action to the transplanted hMSCs. hMSCs could be
found in the transplanted myocardium at 4 weeks
after therapy. This finding indicates that the hMSCs
were not rejected.
Heeschen et al demonstrated that patients
with chronic ischemic heart disease have pro-
foundly reduced neovascularization capacity in
their bone marrow mononuclear cells.24 Further-
more, Rauscher et al have demonstrated the pro-
gressive progenitor cell deficits in older animals.25
Several studies have demonstrated that risk factors
for coronary artery disease correlate with a reduced
number and functional activity of circulating en-
dothelial progenitor cells.15 These data may indi-
cate that MSCs from young and healthy donors
would be the ideal source of cells for cell therapy.
MSCs are defined as self-renewing multipotent pro-
genitor cells with the capacity to differentiate into
several distinct mesenchymal lineages.22 Although
MSCs are a rare population of cells in the bone
marrow, they can be readily grown in culture. It
would be desirable to induce angiogenesis and
myogenesis by MSCs for the treatment of acute
ischemic heart disease.
MSCs have been shown to improve regional
and global left ventricular function and to increase
microvessel formation.9–11 Recently, MSCs have
also been demonstrated to improve myocardial
compliance after acute myocardial infarction.26
However, the effect of MSCs on myocardial re-
generation and neoangiogenesis after chronic
myocardial infarction is not known. Miyahara et al
have demonstrated that monolayered MSCs from
adipose tissue, using cell sheet technology, repaired
scarred myocardium after chronic myocardial in-
farction.27 In the present study, we demonstrated
that direct intramyocardial injection of hMSCs
from bone marrow without any tissue engineer-
ing technique improved cardiac performance after
chronic myocardial infarction in rats. Taken to-
gether, MSCs from different sources may have the
same therapeutic effect on chronic myocardial
infarction.
A previous study has demonstrated that infarct
expansion starts early after myocardial infarction
and cardiac remodeling is continued chronically in
a rat model of myocardial infarction.28 Infarct
healing is usually completed by 3 weeks after
myocardial infarction in rats,29 suggesting that
MSCs may be given late after myocardial infarc-
tion, when the infarct expansion and inflamma-
tion is completed and the infarct scar is fully
matured. Therefore, we injected hMSCs 4 weeks
after myocardial infarction.
In summary, the present study demonstrated
that intramyocardial transplantation of hMSCs
improves cardiac function after chronic myocardial
infarction through enhancement of angiogenesis
and myogenesis in the ischemic myocardium. MSC
transplantation holds promise in the development
of future therapies for myocardial regeneration
for persons who have suffered acute myocardial
infarction.
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